Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Significance: Cancer suppressor p53 is mutated in more than 50% of different human cancers. This study suggests, for the first time, a therapeutic strategy as to how mutant p53 expressing human cancers can be cured by activating its “unmutated homologous proteins”, such as TAp63γ. MiRNA-708, by decreasing the expression of its target gene, it may increase the expression of p53 homologue TAp63γ. Thereby, it may promote tumor suppression. Together, this study suggests a therapeutic strategy as to how one can cure cancer, by activating an alternative cancer suppressor, with an miRNA-708. Thus, pharmacological formulations encompassing “MiRNA-708 activators” can be used to inhibit the progression of human tumors, including p53-mutated human tumors.
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $ 500*
Undisclosed information: How MiRNA-708 increases the expression of TAp63γ
* Research cooperation
Citation: Boominathan, MiRNA-based therapy for p53-mutated human tumors: MiRNA-708 increases the expression of tumor suppressor p53 homologue TAp63γ and inhibits tumorigenesis via down regulation of its target gene, 25/February/2015, 7.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org